Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Rheumatology Reports
Published in: Current Rheumatology Reports 4/2010

01-08-2010

Psoriatic Arthritis: Pharmacotherapy Update

Author: Philip J. Mease

Published in: Current Rheumatology Reports | Issue 4/2010

Login to get access

Abstract

Psoriatic arthritis is a systemic disorder that causes chronic pain, altered physical appearance, and loss of function. The clinical features are diverse, but the core manifestations are psoriasis, peripheral arthritis, axial disease, enthesitis, and dactylitis. Our understanding about the psoriatic arthritis disease state, assessment, and treatment has advanced thanks to significant collaborative efforts by rheumatologists and dermatologists in the development of classification criteria, outcome measures to assess the various clinical domains, and treatment trials with agents also used for diseases such as rheumatoid arthritis and psoriasis. In particular, biologic agents, especially anti-tumor necrosis factor agents, have demonstrated significant efficacy and reasonable safety in all clinical domains of the disease, resulting in amelioration of clinical symptoms, inhibition of structural damage, and improvement in function and quality of life.
Literature
1.
Mease P: Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 2006, 8:348–354.CrossRefPubMed
2.
• Ritchlin CT, Kavanaugh A, Gladman DD, et al.; Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009, 68:1387–1394. This is a summary of several years of work of GRAPPA, which began with a series of evidence-based reviews of therapy of different clinical domains of PsA, followed by discussions at meetings to attempt to gain consensus, and finalized by voting on therapy recommendations for PsA. The recommendations take a grid approach that is based on relative severity and impact of the various clinical domains of PsA.CrossRefPubMed
3.
• Gladman DD, Mease PJ, Strand V, et al.: Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007, 34:1167–1170. This is a summary of the OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials) module conducted by the GRAPPA group, in which the core domains to be assessed in PsA clinical trials were determined.PubMed
4.
Kavanaugh AF, Ritchlin C; GRAPPA Treatment Guideline Committee: Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006, 33:1417–1421.PubMed
5.
Soriano ER, McHugh NJ: Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006, 33:1422–1430.
6.
Nash P: Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006, 33:1431–1434.
7.
Ritchlin CT: Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 2006, 33:1435–1438.
8.
Helliwell PS: Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol 2006, 33:1439–1441.
9.
Strober BE, Siu K, Menon K: Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006, 33:1442–1446.
10.
Boehncke WH, Prinz J, Gottlieb AB: Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006, 33:1447–1451.
11.
Cassell S, Kavanaugh AF: Therapies for psoriatic nail disease. J Rheumatol 2006, 33:1452–1456.PubMed
12.
Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW: Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007, 66(Suppl 3):iii56–iii60. (Published erratum appears in Ann Rheum Dis 2008, 67:140.)CrossRefPubMed
13.
Ku IA, Imboden JB, Hsue PY, Ganz P: Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J 2009, 73:977–985.CrossRefPubMed
14.
Kimhi O, Caspi D, Bornstein NM, et al.: Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007, 36:203–209.CrossRefPubMed
15.
Gladman DD, Antoni C, Mease P, et al.: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005, 64(Suppl 2):ii14–ii17.CrossRefPubMed
16.
• de Vlam K, Gottlieb AB, Fitzgerald O: Biological biomarkers in psoriatic disease. A review. J Rheumatol 2008, 35:1443–1448. This is a review of the current state of knowledge about biomarkers in PsA.PubMed
17.
Maksymowych WP, Landewé R, Tak PP, et al.: Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009, 36:1785–1791.CrossRefPubMed
18.
Maksymowych WP, Fitzgerald O, Wells GA, et al.: Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol 2009, 36:1792–1799.CrossRefPubMed
19.
• Qureshi AA, Dominguez P, Duffin KC, et al.: Psoriatic arthritis screening tools. J Rheumatol 2008, 35:1423–1425. This is a review of the current status of questionnaires being used to screen for PsA in medical practice.PubMed
20.
Duffin KC, Chandran V, Gladman DD, et al.: Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 2008, 35:1449–1453.PubMed
21.
Mease PJ, Antoni CE, Gladman DD, Taylor WJ: Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005, 64(Suppl 2):ii49–ii54.CrossRefPubMed
22.
Mease PJ: Assessment tools in psoriatic arthritis. J Rheumatol 2008, 35:1426–1430.PubMed
23.
Mease PJ, van der Heijde D: Joint damage in psoriatic arthritis: how is it assessed and can it be prevented? Int J Adv Rheumatol 2006, 4:38–48.
24.
Feldman SR, Krueger GG: Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005, 64(Suppl 2):ii65–ii68.CrossRefPubMed
25.
Gladman DD, Mease PJ, Healy P, et al.: Outcome measures in psoriatic arthritis. J Rheumatol 2007, 34:1159–1166.PubMed
26.
Mease PJ, Menter MA: Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006, 54:685–704.CrossRefPubMed
27.
Gladman DD, Inman RD, Cook RJ, et al.: International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 2007, 34:1733–1739.
28.
Gladman DD, Inman RD, Cook RJ, et al.: International spondyloarthritis interobserver reliability exercise—the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007, 34:1740–1745.PubMed
29.
Chandran V, Gottlieb A, Cook RJ, et al.: International multi-center psoriasis and psoriatic arthritis reliability trial (GRAPPA-IMPART): assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 2007, 56:S789–S799.
30.
Nash P, Clegg DO: Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005, 64(Suppl 2):ii74–ii77.CrossRefPubMed
31.
Willkens RF, Williams HJ, Ward JR, et al.: Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum 1984, 27:376–381.CrossRefPubMed
32.
Abu-Shakra M, Gladman DD, Thorne JC, et al.: Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995, 22:241–245.PubMed
33.
Whiting-O’Keefe QE, Fye KH, Sack KD: Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991, 90:711–716.PubMed
34.
Kremer JM, Alarcón GS, Lightfoot RW Jr, et al.: Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994, 37:316–328.CrossRefPubMed
35.
Kalb RE, Strober B, Weinstein G, Lebwohl M: Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009, 60:824–837.CrossRefPubMed
36.
Clegg DO, Reda DJ, Mejias E, et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996, 39:2013–2020.CrossRefPubMed
37.
Gibbs A, Gogarty M, Veale D, et al.: Efficacy of anakinra (Kineret) in psoriatic arthritis, a clinical and immunohistological study. Ann Rheum Dis 2006, 65(Suppl 2):216–217.
38.
Mease PJ, Kivitz AJ, Burch FX, et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264–2272.CrossRefPubMed
39.
Mease PJ, Kivitz AJ, Burch FX, et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006, 33:712–721.PubMed
40.
• Sterry W, Ortonne JP, Kirkham B, et al.: Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010, 340:c147. This study demonstrates excellent psoriasis skin response with etanercept in patients with severe skin disease and PsA, especially in the group that has an “induction” dose with 50 mg twice per week for 12 weeks, followed by standard dose of 50 mg/wk. The higher initial dose did not yield better arthritis, enthesitis, and dactylitis improvements, which were excellent in both dose arms.CrossRefPubMed
41.
Zaba LC, Cardinale I, Gilleaudeau P, et al.: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204:3183–3194. (Published erratum appears in J Exp Med 2008, 205:1941.)CrossRefPubMed
42.
Antoni C, Krueger GG, de Vlam K, et al.; IMPACT 2 Trial Investigators: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150–1157.CrossRefPubMed
43.
van der Heijde D, Kavanaugh A, Gladman DD, et al.: Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 56:2698–2707.CrossRefPubMed
44.
• Antoni CE, Kavanaugh A, van der Heijde D, et al.: Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). J Rheumatol 2008, 35:869–876. This was a long-term observational study on the effect of infliximab in PsA.PubMed
45.
• Raffayova H, Kungurov N, Baranauskaite A, et al.: Infliximab plus methotrexate significantly improves rates of remission for methotrexate naive psoriatic arthritis (PsA) patients compared to methotrexate alone: the RESPOND trial [abstract]. Arthritis Rheum 2009, 60:S470–S471. This was the first study to focus on patients with relatively early PsA (ie, within the first 4 years of disease), in which MTX monotherapy was compared with combination infliximab plus MTX. Results are outstanding, particularly in the combination group, suggesting the potential impact of treating effectively early in the disease process.CrossRef
46.
Mease P, Gladman D, Ritchlin C: Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of ADEPT. Arthritis Rheum 2005, 52:3279–3289.CrossRefPubMed
47.
• Mease PJ, Ory P, Sharp JT, et al.: Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009, 68:702–709. This was a long-term observational study on the effect of adalimumab in PsA.CrossRefPubMed
48.
Karanikolas GN, Arida K, Komninou E, et al.: Combination of adalimumab with cyclosporine-A against single therapy in refractory psoriatic arthritis: an interim analysis of an ongoing, 12-month open, three-arm, randomized trial. Ann Rheum Dis 2009, 68:138–139.
49.
Kavanaugh A, McInnes I, Mease P, et al.: Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60:976–986.CrossRefPubMed
50.
• Kavanaugh A, Mease P, Krueger GG, et al.: Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week efficacy and safety results of the randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2009, 68:136–137. This was a long-term observational study on the effect of golimumab in PsA.
51.
Van den Bosch F, Manger B, Goupille P, et al.: Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010, 69:394–399.CrossRefPubMed
52.
Zochling J, van der Heijde D, Dougados M, Braun J: Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006, 65:423–432.CrossRefPubMed
53.
Wong K, Gladman DD, Husted J, et al.: Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997, 40:1868–1872.CrossRefPubMed
54.
Tam L, Li EK, Shang Q, et al.: TNF-alpha blockade is associated with reduction of carotid intima-media thickness for patients with active psoriatic arthritis—a pilot study [abstract]. Ann Rheum Dis 2009, 68(Suppl 3):659.
55.
Mease PJ, Gladman DD, Keystone EC; Alefacept in Psoriatic Arthritis Study Group: Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006, 54:1638–1645.CrossRefPubMed
56.
Mease PJ, Reich K; Alefacept in Psoriatic Arthritis Study Group: Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009, 60:402–411.CrossRefPubMed
57.
Abrams JR, Lebwohl M, Guzzo C: CTLA4Ig-mediated blockade of T cell co-stimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243–1252.CrossRefPubMed
58.
Mease P, Genovese MC, Ritchlin C, et al.: Abatacept in psoriatic arthritis: results of a phase II study session. Arthritis Rheum 2010 (in press).
59.
• Krueger GG, Langley RG, Leonardi C, et al.: A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007, 356:580–592. This was the first major publication regarding the efficacy of inhibition of IL-12/23 cytokines in the treatment of psoriasis.CrossRefPubMed
60.
• Gottlieb A, Menter A, Mendelsohn A, et al.: Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009, 373:633–640. This was the initial study on the effect of ustekinumab in PsA.CrossRefPubMed
61.
Kimball AB, Gordon KB, Valdes JM, et al.: Retreatment efficacy and long-term safety of the fully human, interleukin-12/23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial. Presented at the 17th Congress on the European Academy of Dermatology and Venereology. Paris, France; September 17–21, 2008.
62.
McInnes IB, Gracie JA: Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:392–397.CrossRefPubMed
63.
Cohen SB, Dore RK, Lane NE, et al.; Denosumab Rheumatoid Arthritis Study Group: Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299–1309.CrossRefPubMed
64.
• Gottlieb A, Korman NJ, Gordon KB, et al.: Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008, 58:851–864. This was a summary of a consensus process conducted among dermatologists on treatment recommendations for PsA.CrossRefPubMed
65.
Mease PJ: Management of psoriatic arthritis. In Rheumatology, edn 5. Edited by Hochberg MC. Philadelphia, PA: Elsevier; 2010 (in press)
Metadata
Title
Psoriatic Arthritis: Pharmacotherapy Update
Author
Philip J. Mease
Publication date
01-08-2010
Publisher
Current Science Inc.
Published in
Current Rheumatology Reports / Issue 4/2010
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0108-z

Other articles of this Issue 4/2010

Current Rheumatology Reports 4/2010 Go to the issue

ReviewPaper

Managing Comorbid Disease in Patients with Psoriatic Arthritis

ReviewPaper

Pitfalls and Opportunities in Measuring Patient Outcomes in Lupus

ReviewPaper

Development of Screening Tools to Identify Psoriatic Arthritis

ReviewPaper

Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues

ReviewPaper

Vitamin D and Systemic Lupus Erythematosus: Bones, Muscles, and Joints

ReviewPaper

Quality-of-Life Measurements Versus Disease Activity in Systemic Lupus Erythematosus
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits